카지노사이트추천

카지노사이트추천 and 카지노사이트추천 Pharmaceutical convened their annual shareholders' meetings at the 카지노사이트추천 Pharmaceutical headquarters in Samseong-dong, Gangnam-gu, Seoul, on March 28th.

At the 64th shareholders' meeting, 카지노사이트추천, represented by Jae-Chun Yoon, provided an overview of its major accomplishments in 2023 and saw the approval of two out of three proposed agenda items. The limits on directors' and auditors' remuneration remained unchanged from the previous year and were endorsed as suggested. However, the proposal regarding stock dividends was not passed. Notably, 카지노사이트추천 invested .4 million in treasury stocks in July last year and is actively pursuing strategies to enhance shareholder value, including initiatives in new drug development and global expansion.

Jae-Chun Yoon, CEO of 카지노사이트추천, emphasized, "Our continuous investments in research and development (R&D) have yielded groundbreaking drugs such as Nabota, Fexuclue, and Envlo, leading to significant market impact and robust growth. 카지노사이트추천 is transitioning into a prominent global healthcare entity."

In 2023, 카지노사이트추천 achieved its highest-ever performance, reporting consolidated sales of .34 billion. 카지노사이트추천 Pharmaceutical also marked its best performance with consolidated sales reaching .02 billion and an operating profit of .6 million. Furthermore, 카지노사이트추천 Bio achieved a milestone by surpassing 0 million in annual sales for the first time since its inception, registering 8.2 million in sales last year. Hanall Biopharma recorded sales of .7 million.

Meanwhile, 카지노사이트추천 Pharmaceutical, represented by Seng-Ho Jeon and Chang-Jae Lee, held its 22nd annual shareholders' meeting simultaneously, successfully passing four proposed agenda items. Chang-Jae Lee was reappointed as an internal director, while Eun-Kyung Park assumed a new role as the ETC Marketing Headquarters Manager. Additionally, Young-Min Cho, a professor at Seoul National University College of Medicine, was appointed as an external director. Geon-Haeng Lee retained the position of in-house auditor. The limits on directors' and auditors' remuneration remained unchanged and were approved as proposed.

Seung-Ho Jeon, CEO of 카지노사이트추천 Pharmaceutical, highlighted, "Through the increased sales contributions of Fexuclue and Envlo, alongside the expanded export activities of Nabota, we achieved record-breaking performance in sales, operating profit, and operating profit margin last year, marking a 'Triple Crown' milestone." He further elaborated, "Looking ahead, 카지노사이트추천 Pharmaceutical will intensify efforts in developing next-generation drugs and global expansion endeavors, with the aim of realizing our vision to attain 9 million in sales from a single new drug, thus realizing the 'One Product, One Trillion' vision."